Stocklytics Platform
Arvinas
ARVN57
$7.28arrow_drop_up3.27%$0.22
NASDAQ - As of Apr 2, 12:17 PM EDT Market Open
ARVN57

$7.28

arrow_drop_up3.27%

Performance History

arrow_drop_down81.09%

(-$31.29 )

Stocklytics logo
Key Stats
Open$6.84
Prev. Close$7.03
EPS-2.77
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$482.77M
PE Ratio-
LOWHIGH
Day Range6.81
7.34
52 Week Range6.79
53.08
Ratios
P/B Ratio2.17
Revenue$263.39M
Operating M. %-98.31%
Earnings$0.00
Earnings Growth %45.85%
EBITDA Margin %-93.24%
ROE %-32.56%
EPS-2.77

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Eli Lilly & Co
LLY84
Price$807.36
Perf. (24h)arrow_drop_down0.03%-$0.31
Market Cap$719.11B
UnitedHealth Group
UNH69
Price$523.51
Perf. (24h)arrow_drop_down0.21%-$1.11
Market Cap$479.14B
Johnson & Johnson
JNJ61
Price$154.83
Perf. (24h)arrow_drop_up1.06%$1.62
Market Cap$397.30B
AbbVie
ABBV67
Price$205.00
Perf. (24h)arrow_drop_down0.73%-$1.51
Market Cap$359.93B

About Arvinas (ARVN)

Arvinas Inc (ARVN) is a pharmaceutical company that focuses on the development of protein degradation therapeutics for the treatment of various diseases. The company utilizes its proprietary platform called PROTAC (PROteolysis TArgeting Chimeras) to design and develop small molecules that can selectively degrade disease-causing proteins within cells. By targeting specific proteins for degradation, Arvinas aims to address diseases that have been previously considered 'undruggable' using traditional approaches. The company's innovative approach has the potential to revolutionize the treatment of cancer and other serious diseases.
With a market capitalization of over $3 billion, Arvinas Inc has quickly gained recognition as a leader in the field of protein degradation therapeutics. The company's stock, ticker symbol ARVN, has seen significant volatility in its price history, reflecting the excitement and anticipation surrounding its novel approach to drug development. Investors and analysts alike have been closely monitoring ARVN's progress and potential for future growth.
Show more
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. John G. Houston Ph.D.
Headquarters
New Haven
Employees
415
Exchange
NASDAQ
add Arvinas to watchlist

Keep an eye on Arvinas

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Arvinas 's (ARVN) price per share?

The current price per share for Arvinas (ARVN) is $7.29. The stock has seen a price change of $0.23 recently, indicating a 3.27% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Arvinas (ARVN)?

For Arvinas (ARVN), the 52-week high is $53.08, which is 628.62% from the current price. The 52-week low is $6.79, the current price is 7.21% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Arvinas (ARVN) a growth stock?

Arvinas (ARVN) has shown an average price growth of -1.65% over the past three years. It has received a score of 19 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Arvinas as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Arvinas (ARVN) stock price performance year to date (YTD)?

As of the latest data, Arvinas (ARVN) has a year-to-date price change of -62%. Over the past month, the stock has experienced a price change of -55.11%. Over the last three months, the change has been -61.43%. Over the past six months, the figure is -70.72%. Looking at a longer horizon, the five-year price change stands at -81.08%.
help

Is Arvinas (ARVN) a profitable company?

Arvinas (ARVN) has a net income of -$198.9M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -98.31% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $263.4M, although specific revenue growth data is currently not available. The gross profit is $263.4M. Operating income is noted at -$250.2M. Furthermore, the EBITDA is -$245.6M.
help

What is the market capitalization of Arvinas (ARVN)?

Arvinas (ARVN) has a market capitalization of $482.78M. The average daily trading volume is 7.16, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level